Voclosporin is used together with other medicines to treat kidney problems in adults with system lupus erythematous. Voclosporin may be used for objectives not provided in this medicine overview. Taking voclosporin may increase your risk of specific cancers such as skin cancer or lymphoma. When taking voclosporin with other medication: To ensure all medicines are secure for you, inform your doctor about all your clinical problems, and if you are pregnant or breastfeeding. Taking voclosporin might increase your risk of particular cancers such as skin cancer or lymphoma. Nevertheless, having untreated active lupus nephritis while pregnant might cause issues such eclampsia. The benefit of treating your kidney troubles may exceed any dangers to the child. Voclosporin is occasionally used in combination with another medication called mycophenolate mofetil. Making use of mycophenolate mofetil while pregnant can cause a losing the unborn baby or abnormality. Both women and men should use reliable contraception to avoid maternity throughout and shortly after therapy with mycophenolate mofetil. Your medical professional might sometimes change your dosage. If you have trouble ingesting a voclosporin pill whole, inform your medical professional. Take voclosporin on an empty stomach, at least 1 hr prior to or 2 hrs after a meal. Your treatment with voclosporin might be delayed or stopped based on the results. Your high blood pressure will also require to be examined frequently. If taking voclosporin is safe or efficient for longer than 1 year, it is not recognized. Take the medicine as soon as you can, but skip the missed dose if you are more than 4 hours late for the dose.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.
|6918486||C63H111N11O12||1214.6||CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C||CC[[email protected]]1C(=O)N(CC(=O)N([[email protected]](C(=O)N[[email protected]](C(=O)N([[email protected]](C(=O)N[[email protected]](C(=O)N[[email protected]@H](C(=O)N([[email protected]](C(=O)N([[email protected]](C(=O)N([[email protected]](C(=O)N([[email protected]](C(=O)N1)[[email protected]@H]([[email protected]](C)C/C=C/C=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C||InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1||BICRTLVBTLFLRD-PTWUADNWSA-N||(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone||7.9||1213.84136802||1213.84136802||279||2380||0||5||12||16||86||0||12||12||0||1||1||0||1|